Aoxiang Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aoxiang Guo has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Bingchen Ge
Department of Pharmacy, the Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, PR China
2 shared publications- Benjie Zhou
School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, China; Shenzhen Key Laboratory of Chinese Medicine Active Substance Screening and Translational Research, Shenzhen 518107, China; Department of Pharmacy, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen 518107, China
1 shared publication Bing Yu
Department of Pharmacy, Shanghai Children’s Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, PR China
1 shared publicationHaiyan Zeng
Clinical Laboratory, University of Chinese Academy of Sciences-Shenzhen Hospital, Shenzhen, China
1 shared publicationHui Chen
Department of Pharmacy, the Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, PR China
1 shared publicationHuixing Wu
School of Pharmacy, Guangdong Medical University, Dongguan, China
1 shared publication
Latest Publications
- Open Access
- 6 December 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
CSDE1 depletion inhibits tumor progression through enhancing B-cell infiltration in NSCLC
Although most immunotherapy research focuses on T cells, increasing evidence highlights the significant role of tumor-infiltrating B lymphocytes (TIL-Bs) in cancer therapy. CSDE1 has been implicated in various cancers and immune responses. This study investigates the role of CSDE1 in lung cancer progression and its impact on the tumor immune microenvironment. We found that CSDE1 promotes lung cancer progression in vivo but not in vitro. Using the tumor-bearing mice model with Csde1 knockout, we demonstrated that Csde1 deletion significantly inhibited tumor growth. Single-cell RNA sequencing revealed that Csde1 knockout reshaped the tumor immune microenvironment, particularly by significantly increasing TIL-B levels, a finding confirmed by flow cytometry and immunofluorescence. Moreover, Csde1 knockout enhanced B-cell-mediated humoral immunity. Notably, depleting B cells in Csde1 knockout mice reversed the inhibitory effect of Csde1 deletion on tumor progression, underscoring the critical role of B cells in this process. These findings suggest that CSDE1 facilitates tumor progression by modulating TIL-Bs and the broader immune microenvironment. This study provides a new potential target and valuable insights into tumor immunotherapy, emphasizing the importance of B cells in cancer treatment strategies.
- 6 December 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessCSDE1 depletion inhibits tumor progression through enhancing B-cell infiltration in NSCLC
Although most immunotherapy research focuses on T cells, increasing evidence highlights the significant role of tumor-infiltrating B lymphocytes (TIL-Bs) in cancer therapy. CSDE1 has been implicated in various cancers and immune responses. This study investigates the role of CSDE1 in lung cancer progression and its impact on the tumor immune microenvironment. We found that CSDE1 promotes lung cancer progression in vivo but not in vitro. Using the tumor-bearing mice model with Csde1 knockout, we demonstrated that Csde1 deletion significantly inhibited tumor growth. Single-cell RNA sequencing revealed that Csde1 knockout reshaped the tumor immune microenvironment, particularly by significantly increasing TIL-B levels, a finding confirmed by flow cytometry and immunofluorescence. Moreover, Csde1 knockout enhanced B-cell-mediated humoral immunity. Notably, depleting B cells in Csde1 knockout mice reversed the inhibitory effect of Csde1 deletion on tumor progression, underscoring the critical role of B cells in this process. These findings suggest that CSDE1 facilitates tumor progression by modulating TIL-Bs and the broader immune microenvironment. This study provides a new potential target and valuable insights into tumor immunotherapy, emphasizing the importance of B cells in cancer treatment strategies.
- Open Access
- 18 October 2023
- Published by Elsevier in Biochemical Pharmacology
- Vol. 218, 115859
Isoliquiritigenin suppresses the progression of malignant melanoma via targeting H2A.Z.1-E2F1 pathway
- 18 October 2023
- Published by Elsevier in Biochemical Pharmacology
- Vol. 218, 115859
Open AccessIsoliquiritigenin suppresses the progression of malignant melanoma via targeting H2A.Z.1-E2F1 pathway